Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 20/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 20/20 | 1.00 |
| ▸ | CHRNB3 | Q05901 | 18/20 | 1.00 |
| ▸ | CHRNA6 | Q15825 | 18/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049284 | 0.86 | CHRNB2 (0.75) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14211345 | 0.83 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL16186299 | 0.80 | CHRNB2 (0.79) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL2938510 | 0.79 | CHRNB2 (0.65) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL12224347 | 0.78 | CHRNB2 (0.64) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL13435652 | 0.78 | CHRNB2 (0.64) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14211242 | 0.78 | CHRNB2 (0.63) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL14211186 | 0.78 | CHRNB2 (0.63) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1711422 | 0.77 | CHRNB2 (0.67) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL15932468 | 0.77 | CHRNB2 (0.67) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | TARGACEPT, INC. (US) | 2012-12-06 | — | — | US | claimed |
| EP-2509982-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Targacept, Inc. (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071758-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-06-16 | — | — | WO | claimed |
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | TARGACEPT INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8802694-B2 | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands | TARGACEPT, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | TARGACEPT, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2509982-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Targacept, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011071758-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTANES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20070225492-A1 | 3,6-Diazabicyclo[3.1.1]Heptane Derivatives with Analgesic Activity | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2007-09-27 | — | — | US | disclosed |
| EP-1751164-A1 | 3,6-DIAZABICYCLOS[3.1.1]HEPTANE DERIVATIVES WITH ANALGESIC ACTIVITY | UNIVERSITA'DEGLI STUDI DI MILANO (IT) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005108402-A1 | 3,6-DIAZABICYCLOS[3.1.1]HEPTANE DERIVATIVES WITH ANALGESIC ACTIVITY | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225492-A1 | 3,6-Diazabicyclo[3.1.1]Heptane Derivatives with Analgesic Activity | OPRK1, OPRM1, OPRD1 | CHRNB2 492/4885CHRNA3 312/4885CHRNA4 621/4885 |
| US-20140315880-A1 | 3,6-DIAZABICYCLO[3.1.1]HEPTAINES AS NEURONAL NICOTINIC ACETYCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA3, CHRNA6 | CHRNB2 9/4885CHRNA3 2/4885CHRNA4 6/4885 |
| US-20120309737-A1 | 3,6-Diazabicyclo[3.1.1]heptanes as Neuronal Nicotinic Acetycholine Receptor Ligands | CHRNA3, CHRNA2, CHRNA6 | CHRNB2 9/4885CHRNA3 1/4885CHRNA4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.